Palatin reports Q2 FY2023 net loss $1.4M, Vyleesi net revenue up 18% QoQ

PALATIN TECHNOLOGIES INC

Net loss of $1.4M ($0.13/share) improved from $8.7M loss ($0.91) YoY; includes $4.7M tax benefit.
Vyleesi net product revenue $1.0M, up 18% vs prior quarter; prescriptions dispensed up 12%.
PL9643 Phase 3 dry eye trial enrollment on track; topline data expected mid-2023.
PL8177 Phase 2 UC trial commenced; interim analysis H1 2023, topline H2 2023.
Cash $21.2M plus $6.5M receivables; sufficient through calendar 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALATIN TECHNOLOGIES INC reported fiscal second quarter ended December 31, 2022 results: revenue $1 million.

Period: fiscal second quarter ended December 31, 2022
Revenue: $1 million
Result: reported results

Exact text from the filing

value metrics, notably net product sales increased 18% and prescriptions dispensed increased 12% over the prior quarter. We are excited that net product revenue of approximately $1 million for the quarter ended December 31, 2022, exceeded Vyleesi operating expenses.” Business Highlights and Recent Updates · Anti-Inflammatory / Autoimmune Programs o PL9643

View on SEC.gov

Browse all earnings releases →

PALATIN TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001654954-23-001757

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.